heart disease, severe comorbidities such as significant liver or renal diseases, concurrent infection or any documented inflammatory illness, such as arthritis or connective tissue diseases, or any other malignancy were excluded.
The etiology of HF was determined to be ischemic when coronary angiography revealed >50% luminal diameter narrowing in at least 1 major epicardial coronary artery, when there was documented myocardial infarction, or when there was HF caused by post-infarction ventricular aneurysm. In those patients with chronic HF without coronary artery disease, where the endomyocardial biopsy revealed findings compatible with dilated cardiomyopathy, the cause of HF was determined to be dilated cardiomyopathy or non-ischemic HF.
The study complied with the Declaration of Helsinki, and the Cheng-Hsin General Hospital's institutional committee on human research also approved the research protocol. Additionally, informed consent was given by all participants.
Clinical Evaluation, Blood Sampling and Measurement of Circulating Levels of Biomarkers
Baseline clinical evaluations of all 96 patients with chronic HF were conducted by a physician. Blood samples were subsequently collected through an indwelling catheter into vacuum tubes (peripheral vein), and processed immediately. The plasma was separated by centrifugation and then frozen to under −20°C, and then stored at that same temperature until analysis.
Assays for N-terminal pro-B-type natriuretic peptide (NTproBNP), high-sensitivity C-reactive protein (hsCRP), leptin, adiponectin, and resistin were done concurrently, to minimize any discrepancies from repeated freeze-thaw cycles. The NTproBNP was determined with Roche Elecsys ® NT-proBNP (Roche Diagnostics, Indianapolis, IN, USA), using an Elecsys 2010 immunoassay analyzer (Roche Diagnostics GmbH). These samples were also measured by immunoassay for hsCRP with a validated, high-sensitivity assay using an autoanalyzer (IMMAGE Immunochemistry Systems, Beckman Coulter, Brea, CA, USA). The plasma concentrations of leptin, adiponectin, and resistin were measured with commercial sandwich enzymelinked immunosorbent assays (R & D Systems, Minneapolis, MN, USA).
Fasting plasma insulin was measured by a double-antibody sandwich immunoassay (Elecsys 2010, Roche Diagnostics GmbH). Insulin resistance was assessed by determining the homeostasis model, according to the homeostasis model assessment of insulin resistance (HOMA-IR) index (defined as fasting plasma glucose [mmol/L] × fasting plasma insulin [pmol/L]/22.5). Creatinine clearance was calculated by the Cockcroft-Gault equation: (140 − age) × weight (kg)/serum creatinine (μmol/L).
The intra-and inter-assay coefficients of variation for each factor in our laboratory were approximately 5% and 10%, respectively.
Clinical Follow-up
Clinical information regarding major adverse cardiac events (MACE), including cardiac death, requirement for heart transplantation, and hospitalization with deteriorating HF, was gathered during a median follow-up of 288 days. The information was collected by the cardiologists in charge, who were unaware of the patients' biomarker levels.
Immunohistochemistry
Heart specimens were dissected from human myocardial tissues and fixed overnight in a 4% buffered formalin solution. They were then embedded in paraffin, and then sectioned into 5-μm thick segments. The paraffin sections were deparaffinized with xylene and stained overnight with mouse anti-human leptin, resistin, or adiponectin antibodies (1:100X, Santa Cruz Biotechnol, Santa Cruz, CA, USA). The sections were washed in phosphatebuffered saline (PBS), and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated rabbit anti-goat or mouse IgG. Next, 0.1% DAB was mixed in Tris HCl and H2O2, after which the mixture was deposited onto slides. After 3-5 min, the stained tissues were observed with a microscope. Finally, the sections were re-washed with PBS, counter-stained with hematoxylin, then mounted using a mounting medium and examined with a microscope.
Western Blot Analysis
In short, cells were lysed with lysis buffer (0.5 mol/L NaCl, 50 mmol/L Tris, 1 mmol/L EDTA, 0.05% SDS, 0.5% Triton X-100, 1 mmol/L PMSF at pH 7.4) for 30 min at 4°C. The cell lysates were centrifuged at 4,000×g for 30 min at 4°C. Protein concentrations in the supernatants were measured using a Bio-Rad protein determination kit (Bio-Rad Laboratories, Hercules, CA, USA). The supernatants were subjected to 12% SDS-PAGE, then transferred for 1 h at room temperature to polyvinylidene difluoride (PVDF) membranes (NEN, Boston, MA, USA), which were then treated for 1 h at room temperature with goat or mouse anti-human leptin, resistin, adiponectin, and α-tubulin antibodies (1:100X, Santa Cruz Biotechnol). The membranes where subsequently washed, then incubated for 1 h at room temperature with horseradish peroxidase-conjugated rabbit anti-goat or mouse IgG. Immunodetection were performed using chemiluminescence reagent plus (NEN, Boston, MA, USA) and exposure to Biomax MR Film (Kodak). The intensity of each band was quantified using a densitometer.
Data Analysis
All values are expressed as mean ± SD. Linear regression analysis was used to determine the correlation between the circu- Because the 3 adipokines were adipose-specific and their levels correlated with BMI, adipokine levels corrected for BMI (c-adipokines) were used in further analyses. The patients were divided into 3 groups according to their NYHA functional classes. Comparisons of the levels of NT-proBNP, hsCRP, c-adiponectin, c-resistin, and c-leptin among these groups were performed by means of a 1-way analysis of variance test.
The HF patients were then divided into 2 groups, depending upon whether or not MACE occurred during follow-up. Univariate comparisons of clinical characteristics and laboratory measurements between these groups were made with Student's t-test or the Mann-Whitney U test for quantitative data, and also with the chi-square test or Fisher's exact test for qualitative data. Kaplan-Meier analyses of HF patient cumulative eventfree rates were done, and stratified into tertiles on the basis of LVEF and biomarker levels. The differences between eventfree curves were tested by log-rank test. In the multivariable Figure 1 . (A) The study patients were divided into 3 groups according to New York Heart Association (NYHA) functional class. The concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), and cadiponectin (adipokine levels corrected for body mass index) increase with the severity of heart failure, especially in the NYHA class IV patients. However, no significant differences in the concentrations of c-resistin and c-leptin were detected among the different NYHA classes. (B) No significant differences in the concentrations of c-adiponectin (adipokine levels corrected for body mass index), c-resistin and c-leptin were detected between patients with ischemic and non-ischemic HF. YIN WH et al.
Cox proportional hazards analyses, the association between plasma c-adipokines and MACE was examined.
For the study of tissue expression, patients were classified clinically as undergoing either elective heart transplantation (U.S. United Network of Organ Sharing; UNOS 2 status) or urgent heart transplantation (UNOS 1 and 1a status).
All values are 2-tailed, and P<0.05 was considered statistically significant. The statistical software package SPSS version 12.0 (SPSS Inc, Chicago, IL, USA) was used for all analyses.
Results

Patients' Characteristics
The baseline characteristics of the 96 patients with chronic HF are shown in Table 1 . More men than women participated in this study. Among the participants, the causes of HF were ischemic cardiomyopathy in 33 (34%) patients and dilated cardiomyopathy in 63 (64%). Mean BMI was 25±5 kg/m 2 . A total of 16 (17%) of the study population had type II diabetes mellitus. Mean systolic blood pressure of the study patients was 116± 17 mmHg, and mean LVEF was 26±9%. A total of 30 (31%) patients were in NYHA class II, 39 (41%) in class III, and 27 (28%) in class IV. All patients were clinically stable at the time blood samples were obtained, while receiving continuous therapy for HF.
Relation Between Levels of the 3 Adipokines and Various Baseline Variables and Their Interrelations With One Another
Significant positive correlations between NT-proBNP and adiponectin, and resistin were observed (r=0.248, P=0.015 and r=0.382, P<0.001, respectively); further substantial correlations were also noted between BMI and adiponectin, leptin, and NTproBNP (r=−0.446, P<0.001; r=0.336, P=0.001; and r=−0.282, P=0.005; respectively).
Among the 3 adipokines, only adiponectin significantly correlated with LVEF (r=−0.230, P=0.024). Significant correlations between resistin and hsCRP, and HOMA-IR (r=0.293, P<0.001 and r=0.340, P=0.001, respectively) were also found. However, there were no significant interrelations among the circulating levels of each adipokine. The concentrations of NT-proBNP, hsCRP, and c-adiponectin increased with the severity of HF, especially in the NYHA class IV patients ( Figure 1A) . However, no significant differences in the concentrations of c-resistin and c-leptin were detected among the different NYHA classes. Moreover, no significant differences in the concentrations of c-adiponectin, c-resistin and c-leptin were detected between patients with ischemic and non-ischemic HF ( Figure 1B) .
Prognosis
The median follow-up period was 288 days (79-403 days, 25-75 th percentiles). There was a 31% (30 of 96) overall event rate in the HF population; 4 of the 96 patients died of cardiac causes during the follow-up, and all 4 had intractable end-stage HF. A total of 9 patients underwent heart transplantation and 17 were re-hospitalized for deteriorating HF. When the 96 patients with chronic HF were divided into 2 groups depending according to MACE during follow-up (Table 2 ), significant differences in the mean BMI, systolic blood pressure, LVEF, creatinine clearance, and mean NYHA functional class were detected between the groups. Furthermore, the concentrations of NT-proBNP, hsCRP, adiponectin and c-adiponectin were significantly higher in the group with MACE than in the event-free group.
Kaplan-Meier analyses of cumulative event-free rates were Figure 2 . Kaplan-Meier analyses of cumulative event-free rates with the heart failure patients, stratified into tertiles on the basis of their left ventricular ejection fraction (LVEF) and levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), and c-adiponectin (adipokine levels corrected for body mass index). The differences in event-free survival curves between the highest (biomarkers) or lowest (LVEF) tertile and the other 2 tertiles were significant for the LVEF, NTproBNP, and c-adiponectin (P=0.0002, P=0.0002, and P=0.0003, respectively). However, the difference in event-free survival curves for hsCRP, c-resistin and c-leptin were insignificant (P=0.0817, P=0.9219 and P=0.3671, respectively). further conducted with the HF patients (Figure 2) . The differences in event-free survival curves between the highest (biomarkers) and lowest (LVEF) tertiles and the other 2 tertiles were significant for LVEF, NT-proBNP, and c-adiponectin (P=0.0002, P=0.0002, and P=0.0003, respectively).
In the multivariable Cox proportional hazards analyses, increasing c-adiponectin level was discovered to be independently associated with MACE (P=0.007) after adjustment for the clinical variables of age, sex, diabetes mellitus, LVEF, systolic blood pressure, serum sodium level, and creatinine clearance ( Table 3) . Additional adjustment for NT-proBNP and hsCRP levels did not attenuate the association between c-adiponectin and MACE, as demonstrated in analysis 5, which showed that high levels of c-adiponectin were associated with a 3-fold increase in the risk of MACE (P=0.037).
Interactions Between NT-proBNP and c-Adiponectin
Because the use of natriuretic peptides in predicting outcomes in HF has become commonplace in the medical world, 16-18 and the primary finding of this study is that elevated c-adiponectin level was associated with adverse outcomes in patients with HF, we further evaluated whether the c-adiponectin level provides Figure 3 . Interactions between concentrations of NT-proBNP and c-adiponectin are shown. The study participants were divided into 2 groups on the basis of whether they had a NT-proBNP level higher or lower than the median level of 1,645 pg/ml, and survival curves between the highest tertile and the other 2 tertiles of c-adiponectin were constructed. The Kaplan-Meier analyses indicated that an elevated adiponectin level was a significant predictor of adverse outcomes in heart failure (HF) patients with higher NT-proBNP levels (A, log-rank P=0.0097) but not in those HF patients with lower NT-proBNP levels (B). The small sample size may preclude demonstration of the prognostic potential of the adiponectin level in the latter. NT-proBNP, N-terminal pro-B-type natriuretic peptide. Figure 4 . Among the 7 patients who underwent heart transplantation during follow-up and were included in the immunohistochemistry study, 3 of them were classified as U.S. United Network of Organ Sharing (UNOS) 2 status, and the other 4 were classified as UNOS 1 and 1a status. The presence of adipokine proteins was observed in the human myocardium specimens through immunohistochemistry study. Among the 3 adipokines studied, only adiponectin was expressed in the myocardium in a significant amount. A significant variation in adiponectin expression among HF patients was found, and the myocardial tissues obtained from the UNOS status 1 and 1a patients (Patients 2, 4, 6, and 7) expressed significantly higher amounts of adiponectin, compared to the myocardium obtained from the UNOS status 2 patients (Patients 1,3, and 5). Adipokines in CHF additional predictive value to the NT-proBNP level. We divided the study participants into 2 groups based on whether they had a NT-proBNP level higher or lower than the median level of 1,645 pg/ml, and constructed survival curves between the highest tertile and the other two tertiles of c-adiponectin. As shown in Figure 3A , in patients with NT-proBNP levels >1,645 pg/ml, an elevated c-adiponectin level was significantly related to prognosis (log-rank P=0.0097). However, in patients with low NTproBNP, the level of c-adiponectin was unrelated to clinical outcome ( Figure 3B) . The small sample size (only 5 of the 48 HF patients with low NT-proBNP levels had elevated c-adiponectin levels) may preclude demonstration of the prognostic potential of the adiponectin level in this group. These results suggest that an elevated serum level of c-adiponectin is an independent predictor of prognosis in patients with HF, especially in those with an elevated NT-proBNP level.
Immunohistochemistry and Western Blot Analysis
Of the 9 patients who underwent heart transplantation during follow-up, 7 gave informed consent and were included in the immunohistochemistry study: 3 of the patients were classified as UNOS 2 status, and the other 4 as UNOS 1 and 1a status.
Adipokine proteins were observed in the human myocardium specimens examined in the immunohistochemistry study. Among the 3 adipokines studied, only adiponectin was expressed in the myocardium in a significant amount (Figure 4) . Moreover, a significant variation in adiponectin expression among HF patients was also found and, as noted before, the myocardial tissues obtained from the UNOS status 1 and 1a patients (Patients 2, 4, 6, and 7) expressed significantly higher amounts of adiponectin, compared to the myocardium obtained from the UNOS status 2 patients (Patients 1, 3, and 5) .
Western blot analysis ( Figure 5 ) confirmed the finding from the immunohistochemistry study that an obvious difference in adiponectin expression existed between myocardial tissues obtained from the UNOS status 1 and 1a patients, and those from UNOS status 2 patients.
Discussion
This study demonstrated that the circulating levels of leptin, adiponectin, and resistin were significantly correlated with that of NT-proBNP. The circulating concentrations of adiponectin, corrected for BMI, increased with the severity of HF and high levels of c-adiponectin were predictive for the development of adverse clinical outcomes. Nonetheless, the tissue expressions of the 3 adipokines in myocardium of patients with chronic HF varied. The myocardial tissues obtained from the recipient hearts of the UNOS status 1 and 1a patients expressed significantly higher amounts of adiponectin compared to those from UNOS status 2 patients.
The most widely studied adipokine in HF is leptin. Previous studies suggest that leptin levels are elevated in HF patients with and without cachexia. 4-8 Leptin has been implicated in the pathogenesis of impaired insulin sensitivity, abnormal tissue catabolism, and changes in body composition, specifically, adipose tissues, 5-8, 10 and may play a vital role in the regulation of respiration in HF patients. 11 Moreover, a recent study indicates that the failing human heart increases expression of leptin and its receptor and that mechanical unloading downregulates this increase. Further, a cardioprotective role for leptin in the failing human heart is suggested through the activation of signal transducer and activator of transcription-3 and AMP-activated kinase signaling. 12 But contrary to such claims made by previous studies on leptin, we observed neither an alteration in the circulating and tissue levels of leptin in patients with HF, nor any correlation between leptin levels and insulin resistance; indeed, no significant difference in c-leptin levels among patients with chronic HF of different functional classes was detectable in our study. One possible explanation for the apparent discrepancy is that plasma leptin levels in HF patients alter according to the clinical stages; that is, leptin levels increase in less severely affected HF patients but decrease when end-stage HF is reached. 19, 20 Because we did not measure changes in functional class,weight or leptin during follow-up, it is possible that the study population perhaps included a highly heterogeneous group of HF patients in all clinical stages. Although the increased and decreased leptin levels merged, the mean values in the study patients of different functional classes were not markedly different.
Adiponectin has been reported to play an important role in the regulation of cardiac remodeling through inhibition of hypertrophic signaling in the myocardium. 21, 22 In addition to its vascular effects that indirectly protect ischemic-reperfused cardiomyocytes, in vitro studies have demonstrated that adiponectin promotes cell survival and inhibits cell death. 21-24 Moreover, adiponectin protects against cardiac fibrosis and dysfunction. 21,25, 26 Many previous studies examined the prognostic value of adiponectin in patients with HF. 4,13-15, 21 Our study confirmed the findings that showed which plasma adiponectin levels were clearly correlated with NT-proBNP levels and BMI, and that showed high adiponectin levels were independently predictive of clinical outcomes.
Recent studies have demonstrated that adiponectin is present in damaged myocytes, and that it is synthesized and secreted by isolated cardiomyocytes, suggesting that damaged cardiac cells possess an adiponectin autocrine/paracrine system. 27-29 Although the amount of locally synthesized cardiac adiponectin is too small to contribute significantly to circulating concentrations of adiponectin, as compared to that of adipose tissue, the adiponectin generated locally may still determine the biological effects on myocardial cells. Skurk et al have dem- onstrated the existence of such a local cardiac adiponectin system, which is dysregulated in dilated cardiomyopathy, and they suggested that adiponectin has a part to play in the pathogenesis of dilated cardiomyopathy. 30 In our study, a significant difference in adiponectin expression between myocardial tissues obtained from recipient hearts of UNOS status 1 and 1a patients and those of UNOS status 2 patients was demonstrated. Although the number of specimens in our study is limited, it seems that the myocardial tissue expression of adiponectin is related to the severity of HF. The reason why myocardial tissues obtained from the recipient hearts of UNOS status 1 and 1a patients expressed significantly higher amounts of adiponectin compared to those from UNOS status 2 patients remains unclear. One possible mechanism is that the elevated circulating adiponectin in HF could accumulate or bind to the injured matrix with abundantly expressed collagen, 25,31 probably acting like B-type natriuretic peptide as a counter-regulating hormone in HF pathophysiology, and leading to protection against the progression of myocardial injury. Recent studies have demonstrated that adiponectin accumulates in injured heart tissues. 25, 31 Another possible explanation is that in advanced HF, anti-failure therapy may increase the tissue expression of adiponectin. In an animal model of acute myocarditis, the expression of adiponectin could be induced by the angiotensinreceptor blocker, candesartan, probably providing cardioprotective effects against HF. 32, 33 Adipokine resistin, expressed in white adipose tissue specifically, antagonizes insulin-stimulated glucose metabolism, inhibits adipocyte differentiation and has a direct proinflammatory effect on vascular endothelial cells. 34 Although plasma resistin levels in patients with acute coronary syndrome are elevated, and increased resistin levels are considered to be a marker of myocardial ischemia and injury, 35 another recently published study failed to demonstrate a cardioprotective effect of resistin against ischemia-reperfusion injury. 36 On the contrary, overexpression of resistin in adult cultured cardiomyocytes significantly alters myocyte mechanics by depressing cell contractility as well as contraction and relaxation velocities, and promotes cardiac hypertrophy. 37 Serum resistin had been reported to be independently associated with the risk for incident HF in older people, related to the severity of HF, and associated with a high risk for adverse cardiac events in HF patients. 9, 38 However, in the present study of patients with chronic HF and systolic dysfunction, even though the plasma resistin levels were significantly correlated with NT-proBNP, hsCRP, and HOMA-IR, the Cox proportional hazard analyses failed to prove c-resistin was an independent predictor of adverse clinical outcome. Given that the balance in the concentrations of adipokines, such as adiponectin and resistin, determines the vascular inflammation status, 39 resistin may be considered a marker of vascular inflammation and a mediator of the metabolic and endocrine imbalances accompanying HF. The interplay and interactions of resistin with other neurohumoral factors, cytokines and cell-signaling pathways remain to be fully determined.
Clinical Implications
Neurohormonal and immune activation and inflammation can be important to the catabolic processes in the pathophysiology of HF. These processes may contribute to symptoms, exercise intolerance, weight loss and disease progression. 1-3 In our study, no significant differences in the concentrations of c-adiponectin, c-resistin and c-leptin were detected between patients with ischemic and non-ischemic HF. Similar findings have been reported by Tamura et al. 14 Therefore, the increased c-adiponectin levels in patients with HF seems to be a general phenomenon that is unrelated to the presence or absence of coronary artery disease, which suggests that HF is the final common pathway of a variety of cardiac disorders, including ischemic and non-ischemic heart diseases. Moreover, the adiponectin levels may add to the predictive value of NT-proBNP, an established predictor of HF outcomes. Thus, the combined evaluation of both markers may be superior as a method of risk detection to measurement of either marker alone, especially in those who have elevated NT-proBNP levels, as shown in Figure 3 . Finally, the association between adiponectin and outcomes and severity of HF could be cause or effect. Therefore, the effects of anti-failure drugs on adipokines and body wasting in patients with HF are worthy topics for future research; in truth, whether adipokines may become potential targets in the treatment of HF also calls for more studies.
Study Limitations
Several limitations of the present study are acknowledged. First, this study is limited by its relatively small sample size. The relationship of the biomarkers to prognosis on the basis of limited numbers of MACE is relatively weak. Therefore, further and larger studies are certainly needed to confirm or refine our findings. Second, the present investigation did not measure catecholamines, angiotensin II, or endothlin-1 plasma levels, nor did we measure other cytokines secreted by adipose tissue, such as tumor necrosis factor-α, interleukin-6, and so forth. It is known that the levels of these factors are increased in patients with HF and may be related to adipose-specific adipokines, so they have a stronger association with survival rate. Third, although these significant cross-sectional associations suggest that our assay methods were reasonable and accurate, serial measurements would still be needed to quantify and correct possible underestimation or overestimation in associations, because of likely fluctuations in adipokine values within an individual over time, and the causal interrelationship between these parameters. Finally, the cutoff points used for adipokines in the present study population may not be applicable in other HF populations.
Conclusions
Among the 3 adipokines discussed, high adiponectin levels can provide independent prognostic information about patients with chronic HF. Moreover, our study offers additional data to the already available, but scarce information about tissue expressions of adipokines in end-stage HF patients. These data support the view that circulating adipokines reflect inflammatory events and may serve as prognostic markers for chronic HF. Even if these cytokine disturbances may not be the ultimate cause of HF, they may nevertheless represent a 'final common pathway' that is independent of the etiology of cardiac disease.
